Clinical Trials Browser

Phase 2/3 × IFL protocol × 30 days × Clear all

NCT03081143 2026-04-14

RAMIRIS

Phase 2/3 Active not recruiting

Gastrointestinal

Advanced Gastric or EGJ Cancer

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms